Skip to main content

Table 3 Univariate analysis of the influence of clinical data on the occurrence of AEs

From: Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease

 

EDS and sleep attacks

Visual hallucinations

Nausea and vomiting

Orthostatic hypotension

OR (95% CI)

p value

OR (95% CI)

p value

OR (95% CI)

p value

OR (95%CI)

p value

Sex (male = ref.)

0.75 (0.43–1.32)

0.322

0.74 (0.40–1.38)

0.347

3.22 (1.77–5.85)

< 0.001

0.706 (0.41–1.23)

0.218

Side of first symptoms (left = ref.)

Both

0.83 (0.29–2.38)

0.726

0.35 (0.08–1.63)

0.181

1.06 (0.37–3.08)

0.911

1.72 (0.65–4.57)

0.278

Right

1.14 (0.64–2.03)

0.660

1.30 (0.69–2.46)

0.412

1.07 (0.58–1.97)

0.824

0.98 (0.55–1.74)

0.933

Tremor-predominant PD (No = ref.)

0.82 (0.41–1.65)

0.578

0.92 (0.43–1.99)

0.837

0.89 (0.43–1.84)

0.743

0.57 (0.29–1.13)

0.107

Ever being treated with DAs (No = ref.)

1.81 (0.91–3.58)

0.089

1.79 (0.84–3.85)

0.134

3.19 (1.41–7.19)

0.005

0.74 (0.40–1.37)

0.337

Age at diagnosis

1.00 (0.98–1.02)

0.871

0.97 (0.94–0.99)

0.006

0.97 (0.95–1.00)

0.026

1.01 (0.99–1.04)

0.281

Disease duration

1.04 (1.00–1.08)

0.066

1.13 (1.08–1.19)

< 0.001

1.02 (0.98–1.06)

0.366

1.04 (1.00–1.08)

0.080

Levodopa treatment duration

1.04 (0.99–1.08)

0.112

1.15 (1.09–1.21)

< 0.001

1.00 (0.96–1.05)

0.940

1.07 (1.02–1.12)

0.005

LED at enrolment

1.00 (1.00–1.00)

0.106

1.00 (1.00–1.00)

0.004

1.00 (1.00–1.00)

0.869

1.00 (1.00–1.00)

0.085

 

Peripheral edema

Impulse control disorders

Motor fluctuations

Dyskinesia

Sex (male = ref.)

0.66 (0.33–1.31)

0.229

0.58 (0.26–1.29)

0.181

0.97 (0.57–1.64)

0.899

1.03 (0.61–1.76)

0.905

Side of first symptoms (left = ref.)

Both

2.44 (0.79–7.50)

0.120

0.33 (0.04–2.69)

0.300

0.37 (0.13–1.06)

0.065

0.59 (0.21–1.68)

0.324

Right

1.56 (0.75–3.27)

0.234

1.22 (0.56–2.68)

0.613

1.15 (0.66–2.01)

0.620

1.24 (0.71–2.17)

0.446

Tremor-predominant PD (No = ref.)

1.02 (0.43–2.39)

0.969

0.97 (0.37–2.54)

0.954

0.40 (0.19–0.83)

0.014

0.33 (0.16–0.67)

0.002

Ever being treated with DAs (No = ref.)

2.44 (0.97–6.14)

0.058

12.00 (1.60–90.21)

0.016

6.82 (3.28–14.19)

< 0.001

5.43 (2.50–11.81)

< 0.001

Age at diagnosis

1.00 (0.97–1.03)

0.977

0.93 (0.90–0.96)

< 0.001

0.89 (0.86–0.92)

< 0.001

0.88 (0.85–0.91)

< 0.001

Disease duration

1.010 (0.96–1.06)

0.682

1.04 (0.99–1.0)

0.114

1.44 (1.31–1.58)

< 0.001

1.33 (1.24–1.44)

< 0.001

Levodopa treatment duration

1.03 (0.98–1.08)

0.310

1.01 (0.95–1.07)

0.872

1.42 (1.29–1.56)

< 0.001

1.32 (1.22–1.42)

< 0.001

LED at enrolment

1.00 (1.00–1.00)

0.212

1.00 (1.00–1.00)

0.140

1.01 (1.00–1.01)

< 0.001

1.00 (1.00–1.00)

< 0.001

  1. Significant and nominally significant results are written in bold text